Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-01-26
2001-07-17
Huang, Evelyn Mei (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S101000
Reexamination Certificate
active
06262064
ABSTRACT:
BACKGROUND OF THE INVENTION
Abnormal transmission to receptors in the central nervous system (CNS) have been implicated in wide variety of diseases, such as Parkinson's disease, psychosis, and many others. Currently, many therapies for these diseases are based upon the use of a medicament as an agonist to stimulate a receptor, or as an antagonist to block a receptor. For example, the treatment of psychosis has been associated with medicament antagonism with dopaminergic receptors.
The ability of a medicament to be effective in vivo to effectively interact with CNS receptors depends upon many factors, including the binding affinity of the medicament for a receptor, the medicaments ability to cross the blood-brain barrier, and the selectivity of the medicament for a targeted receptor. For example, to treat psychotic activity a medicament would be a selective antagonist for the D4 dopamine receptor.
To date, many medicaments with good binding affinities for a particular CNS receptor also bind to non-targeted receptors, often resulting in undesirable side-effects. For example, common side-effects of anti-psychotic drugs include extrapyramidal side-effects. Similarly, some atypical anti-psychotic drugs, such as clozapine which is selective for the D4 receptor, have not exhibited extrapyramidal side-effects but have had severe effects upon the patient's white blood cells, such as agranulocytosis.
Consequently, compositions are needed that can cross the blood-brain barrier to act in vivo and selectively target a CNS receptor without causing severe extrapyramidal side-effects, agranulocytosis or other side-effects associated with current medicaments.
SUMMARY OF THE INVENTION
The present invention relates to a composition, and method of use, of an octahydrobenzo[f]quinoline-based compound represented by the following structural formula:
In this formula, R
1
is —OH or —OCH
3
and R
2
is —H, —OH or —OCH
3
. In addition, R
3
is a C1 to C4 alkyl group. Furthermore, R
4
is an aryl group, wherein examples of suitable aryl groups, as defined herein, include phenyl and thienyl groups.
The method of this invention relates to the use of the claimed compositions to treat psychotic disorders, to treat Parkinson's disease, or to sedate a mammal by administering an effective amount of a claimed composition.
The benefits of this invention include the ability to treat psychotic disorders without causing extrapyramidal side-effects or agranulocytosis associated with other anti-psychotic medicaments.
REFERENCES:
patent: 4228169 (1980-10-01), Johnson et al.
patent: 4341786 (1982-07-01), DeMarinis et al.
patent: 4405626 (1983-09-01), Johnson
patent: 4612316 (1986-09-01), Andersson et al.
patent: 4678791 (1987-07-01), Napier et al.
patent: 5030636 (1991-07-01), Imhof et al.
patent: 0127597 (1984-03-01), None
patent: 0 059 553 (1982-09-01), None
patent: 0 109 039 (1984-05-01), None
patent: 2 138 815 (1984-10-01), None
patent: WO 84/04303 (1984-11-01), None
Wikstrom, H., et al., “N-Substituted 1,2,3,4,4a,5,6,10b-Octahydrobenzo[f]quinolines and 3-Phenylpiperidines: Effects on Central Dopamine and &sgr; Receptors,”J. Med. Chem. 30:2169-2174 (1987).
Wikstrom, H., et al., “Monophenolic Octahydrobenzo[f]quinolines: Central Dopamine- and Serotonin-Receptor Stimulating Activity,”J. Med. Chem. 25: 925-931 (1982).
Cannon, J.G., et al. “Rigid Congeners of Dopamine Based on Octahydrobenzo[f]quinoline: Peripheral and Central Effects,”Journal Medicinal Chemistry 22(4):341-347 (1979).
Titeler, M. and Seeman, P., “Presynaptically Acting Catecholamines Bind to &agr;2-Adrenoceptors Labelled by3H-Clonidine,”European Journal of Pharmacology 67:187-192 (1980).
Ilhan, M., et al., “Dopamine Receptor Stimulating and Alpha Adrenoceptor Blocking Actions of trans (CS-265) and cis (CS-263) Isomers of Nonhydroxylated N-Propyl Octahydrobenzo[f]quinoline,”The Journal of Pharmacology and Experimental Therapeutics 231(2):361-366 (1984).
Van de Waterbeemd, H., et al., “Quantitative Structure—Activity Relationships and Eudismic Analyses of the Presynaptic Dopaminergic Activity and Dopamine D2 and &sgr; Receptor Affinities of 3-(3-Hydroxyphenyl)piperidines and Octahydrobenzo[f]- quinolines,”J. Med. Chem. 30:2175-2181 (1987).
Cannon, J.G., et al., “Conformationally Restricted Congeners of Dopamine Derived from Octahydrobenzo[g]quinoline and Octahydrobenzo[f]quinoline,”J. Med. Chem. 27:190-195 (1984).
Cannon, J.G., et al., “Centrally Acting Emetics. 10. Rigid Dopamine Congeners Derived from Octahydrobenzo[f]quinoline,”Journal of Medicinal Chemistry 19(8):987-993 (1976).
Cannon, J.G., et al., “cis- and trans-4-n-Propyl-1,2,3,4,4a,5,6,10b-Octahydrobenzo[f]quinolines,”Journal of Pharmaceutical Sciences 74(6):672-675 (1985).
Cannon, J.G., et al., “p-Dimethoxy-Substituted trans-Octahydrobenzo[f]- and [g]quinolines: Synthesis and Assessment of Dopaminergic Agonist Effects,”J. Med. Chem. 29:2529-2534 (1986).
Van Oene, J.C., et al., “trans-N-n-Propyl-7-Hydroxy-Octahydrobenzo(f)Quinoline, A Rigid 3-PPP Analogue with Greater Potency but Lack of Selectivity for Dopamine Autoreceptors,”European Journal of Pharmacology 87:491-495 (1983).
Maixner, W., et al., “Pharmacological Effects of 2-Aminotetralins, Octahydrobenzo[f]Quinolines and Clonidine on the Isolated Guinea Pig Ileum,”European Journal of Pharmacology 71:475-482 (1981).
Kocjan, D. and Hadzi, D., “Conformationally Restricted Dopamine Congeners—A Molecular Mechanics-Based Study,”J. Pharm. Pharmacol. 35:780-785 (1983).
Sokoloff, P., et al., “Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics,”Nature 347:146-151 (1990).
Caine, S.B., et al., “Modulation of Cocaine Self-Administration in the Rat Through D-3 Dopamine Receptors,”Science 260: 1814-1816 (1993).
Seeman, P., et al., “Dopamine D4 receptors elevated in schizophrenia,”Nature 365:441-445 (1993).
Van Tol, H.H.M., et al., “Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine,”Nature 350:610-614 (1991).
Kaiser, C. and Jain, T., “Dopamine Receptors: Functions, Subtypes and Emerging Concepts,”Medicinal Research Reviews 5:145-211 (1985).
Manallack, D.T. and Beart P.M., “A Three Dimensional Receptor Model of the Dopamine D2 Receptor from Computer Graphic Analyses of D2 Agonists,”J. Pharm. Pharmacol. 40:422-428 (1988).
Bradbury, A.J., et al., “A Comparison of Dopamine Agonist Action to Inhibit Locomotor Activity and to Induce Stereotyped Behaviour in the Mouse,”European Journal of Pharmacology 105:33-47 (1984).
Bradbury, A.J., et al., “Inhibition and Facilitation of Motor Responding of the Mouse by Actions of Dopamine Agonists in the Forebrain,”Neuropharmacology 23(9):1025-1031 (1984).
Berlan, M., et al., “Pharmacological prospects for &agr;2-adrenoceptor antagonist therapy,”TIPS 13:277-282 (1992).
Froimowitz, M., et al., “Derivatives of Octahydrobenzo(f)quinolines with High Affinity for Dopaminergic Receptors,” CPDD 1993 Annual Scientific Meeting Abstracts, May 19, 1993 (abstract).
kaiser C and Jain T. Medical Research Reviews. 5(20 145-229, 1985.
Froimowitz Mark
Jacob James N.
Hamilton Brook Smith & Reynolds P.C.
Huang Evelyn Mei
The Board of Governors for Higher Education
LandOfFree
Octahydrobenzo[f]quinoline-based receptor agonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Octahydrobenzo[f]quinoline-based receptor agonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octahydrobenzo[f]quinoline-based receptor agonists... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2467230